Adenoid cystic carcinoma of the breast: the decisions you may face

Cancer page →Second-opinion finder →

1 treatment setting, 0 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Early / localised

Localised disease

One path named

Surgery with clear margins, radiotherapy after breast conservation, and no chemotherapy for the classical type in the European working group consensus; the solid-basaloid variant is managed as high-grade triple-negative disease.

The path, in plain words

Sentinel lymph node biopsyStandard of care

Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.

Avoids lymphoedema from full dissection

Also referenced:Lumpectomy (breast-conserving surgery)Mastectomy

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Sentinel lymph node biopsy

False negatives in ~5-10%

Questions to ask about this decision

Is Sentinel lymph node biopsy the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (localised disease), which of the standard options do you recommend and why?
Why: Guideline options include: Surgery with clear margins, radiotherapy after breast conservation, and no chemotherapy for the classical type in the European working group consensus; the solid-basaloid variant is managed as high-grade triple-negative disease.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care